---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-012885"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:51:14.874468+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Batoclimab TED Phase 3 misses endpoint; Roivant starts brepocitinib LPP trial; $4.3B cash

## Summary
- Preliminary cash, cash equivalents and marketable securities as of Mar 31, 2026: ~$4.3B.
- Repurchased 3,956,362 common shares for ~$109.7M in Q4 fiscal 2026.
- Immunovant's two Phase 3 studies of batoclimab in TED failed to meet primary endpoint of ≥2mm proptosis responder rate at Week 24.
- Priovant began Phase 2b/3 trial of brepocitinib in lichen planopilaris; first subjects enrolled Mar 2026.
- Brepocitinib NDA for dermatomyositis granted Priority Review; PDUFA target in Q3 calendar 2026.

## SEC filing metadata
- accession: 0001140361-26-012885
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/0001140361-26-012885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/ef20069685_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-012885
- JSON: https://secwatch.observer/filing/0001140361-26-012885.json
- Plain text: https://secwatch.observer/filing/0001140361-26-012885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.